EGFR and non-small cell lung carcinoma: In view of the EGFR mutations in NSCLC, the development of EGFR tyrosine kinase inhibitors (EGFR‐TKIs), such as gefitinib, afatinib, and oxetinib, has demonstrated enhanced therapeutic effects in NSCLC patients with EGFR mutations.